QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

Impact · against what's priced in

QuidelOrtho's guidance for FY2026 marks a pivot toward positive free cash flow and durable growth, reducing the risk of continued COVID-related volatility. While the CFO's retirement introduces minor leadership uncertainty, the projected EBITDA expansion and revenue growth provide a positive catalyst for valuation.

QDEL+0.60

No priced-in read yet

In context

The company expects a significant swing in free cash flow from a $(77) million loss in FY25 to positive $120-$160 million in FY26, alongside revenue growth forecasts of $2.7-$2.9 billion.

Read from the article alone

• healthcare▲2%
• guidance▲1%
• cash flow
• earnings
• QDEL
• cfo retirement
• diagnostics
• ebitda